Davood KHoda Amorzideh on VTE and Bleeding in Cancer
Davood KHoda Amorzideh, Clinical Cardiologist at Farjam Heart Clinic, shared on LinkedIn:
”In the AVERT post-hoc analysis, cancer patients at intermediate-high VTE risk (Khorana_score ≥2) with elevated baseline GDF_15 had increased VTE risk, while elevated NT proBNP and CRP levels predicted bleeding.
Increasing hs-TnT levels from baseline to 1 month was associated with increased VTE risk.
Steven Hawken, Marc Carrier, Philip Wells, Dylan Burger, Tzu-Fei Wang’‘
Read the full article here.
Article: Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers Open Access
Authors: Danielle Carole Roy , Tzu-Fei Wang , Ranjeeta Mallick , Dylan Burger , Marc Carrier , Philip Wells , Steven Hawken
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 22, 2026, 09:01Ash Paul: Comparing Left Atrial Appendage Occlusion and Oral Anticoagulation
-
Sep 22, 2026, 08:50Emily Horner: Lipoprotein(a) Links Oxidized Phospholipids to Platelet Hyperactivity
-
Sep 22, 2026, 08:42Sally Mandour: Bone Marrow Needle Gauge Explained
-
Sep 22, 2026, 08:39Alessandro Sionis: Navigating Anticoagulation in Mechanical Circulatory Support
-
Sep 22, 2026, 08:28Raghavendra Rao: The Latest Research on Varicose Veins
-
Sep 22, 2026, 08:23Aravind Palraj: Three Essential Tests in Antiphospholipid Syndrome
-
Sep 22, 2026, 08:18Salih Ehsan: Understanding the Major Glycoproteins on Platelets
-
Sep 22, 2026, 08:06Tim Brümmendorf: Exciting Sessions Ahead at ESHBMFS2026
-
Sep 22, 2026, 08:05Samin Mohsenian: Can Factor VII Activity Predict Bleeding Severity?